Catalent, Novo Holdings

Novo Holdings set to close $16.5B Catalent buy in 'coming days' after deal clears antitrust hurdles
After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to unwrap its $16.5 billion present just in time for the holidays.
Pharmalittle: We’re reading about Novo Holdings proceeding with Catalent deal, Sanofi threatened with sanctions, and more
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge the deal
Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.
Novo Holdings’ purchase of Catalent set to close after regulators’ green light
The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three Catalent drug manufacturing plants.
Novo Nordisk says Catalent buyout to close soon as regulatory conditions met
Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory conditions to buy the U.
Novo’s takeover of Catalent set to proceed after FTC declines to challenge deal
Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the Federal Trade Commission decided not to challenge the deal. It’s expected to close in the coming days.
Catalent And Novo Holdings Complete All Regulatory Closing Conditions For Merger
Catalent Inc. (CTLT) and Novo Holdings A/S announced that the companies have fulfilled all regulatory closing conditions for their
Novo Nordisk Set to Close Catalent Deal Without FTC Challenge
Novo Nordisk A/S can advance with its acquisition of factories from contract development and manufacturing organization Catalent Inc. after the Federal Trade Commission declined to challenge the deal.
MM&M21h
Novo Holdings’ $16.5B deal for Catalent clears last regulatory hurdle
Novo Holdings is on track to acquire Catalent, a global contract development and manufacturing organization, in a $16.5 ...
BioSpace8h
Novo Holdings Gets FTC’s Go-Ahead for Contentious $16.5B Catalent Acquisition
Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to ...
Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...
WFIU47m
Danish pharma giant cleared to buy Catalent
Europe’s biggest corporation is taking over Catalent, which runs a factory in Bloomington. The Federal Trade Commission ...
BioSpace4h
Novo Deepens Denmark Commitment With $1.2B Rare Disease Production Facility
Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which ...